A comprehensive view of FujiFilm Diosynth Biotechnologies. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.
FUJIFILM Diosynth Biotechnologies expands manufacturing agreement with argenx for the production of the autoimmune disease drug efgartigimod; the deal builds upon a previous agreement announced in October 2022
Published:
March 25, 2024
by Fujifilm Corp.
|
Fujifilm Diosynth Biotechnologies names Richard McAvoy as CFO effective April 1; McAvoy most recently served as VP of business support and site head for Fujifilm's US$2.0B large-scale cell culture manufacturing facility in Holly Springs, North Carolina
Published:
March 11, 2024
by Fujifilm Corp.
|
FujiFilm Diosynth Biotechnologies enters a 10-year deal with Better Energy to source 40 GWh of renewable energy annually from 2025; the electricity will cover the total electricity consumption at FujiFilm's Hillerod, Denmark manufacturing site
Published:
March 07, 2024
by Gulf Oil & Gas (Egypt)
|
FUJIFILM Diosynth Biotechnologies signs a 10-year agreement with Better Energy to source 40 GWh of renewable energy annually; deal expected to supply total electricity consumption at the company’s Hillerod, Denmark biopharmaceutical manufacturing site
Published:
February 29, 2024
by FUJIFILM Holdings America Corp.
|
FUJIFILM Diosynth Biotechnologies partners with SHL Medical to expand its autoinjector services; the partnership aims to streamline production, enhance efficiency, and increase manufacturing capacity to 30 million units per year starting from 2025
Published:
January 08, 2024
by FUJIFILM Holdings America Corp.
|
Ask us about our Tissue & Hygiene market view